Somatostatin-active polypeptide composition
AssigneeApplied Research Systems ARS Holding N.V.
InventorsManuel R. Puyol, Diego R. Puyol
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions for use in the prevention or treatment of diseases and dysfunctions associated with pathological contraction of mesangial cells and other contractile cells responsive to angiotensin II and/or oxygen free radicals, comprise as an active ingredient one or more somatostatin-active polypeptides. The somatostatins are particularly useful for the treatment or prevention of renal dysfunction.
Claims13
A method of prophylaxis of a human or animal subject at risk of renal dysfunction, said dysfunction being associated with a pathological contraction of mesangial cells responsive to angiotensin II and/or oxygen free radicals, which comprises the step of:
- administering a somatostatin-active polypeptide to said subject in a dose effective to prevent said pathological contraction of mesangial cells, wherein said dose is from 10-150 .mu.g/kg/day.
A method of treatment of a human or animal subject suffering from renal dysfunction, said dysfunction being associated with pathological contraction of mesangial cells responsive to angiotensin II and/or oxygen free radicals which comprises the step of:
- administering a somatostatin-active polypeptide to said subject in a dose effective to reverse said pathological contraction of mesangial cells, wherein said dose is from 10-150 .mu.g/kg/day.
Dependencies are inferred from the claim text.